Report top-line results from the Phase 2 clinical trial of ADX-2191 in retinitis pigmentosa
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 9 Mar 2023
- Due
- 30 Jun 2023
- Delivered
- June 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Top-line results from the Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa Expected in the First Half of 2023”
What we found
Evidence strength A What the grades mean
The company announced top-line results from the Phase 2 clinical trial of ADX-2191 in retinitis pigmentosa in June 2023, meeting the first-half 2023 deadline.
-
A Aldeyra Therapeutics, Inc. 10-K filed 2024-03-07
“In June 2023, we announced top-line results from the Phase 2 clinical trial of intravitreal ADX-2191 in patients with retinitis pigmentosa.” ✓ confirmed on the page
Market reaction: the shares moved -17.6% against the S&P 500 over the three sessions around the disclosure (6 Mar 2024 to 11 Mar 2024). What this measures
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 1 versions
-
Version 1 · original · stated 9 Mar 2023
Deadline 30 Jun 2023 (“the first half of 2023”) · wording expected
-
Version 2 · stated 19 Dec 2023
Deadline 31 Dec 2024 (“in the second half of 2024”) · wording expected
“Results are expected in the second half of 2024.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Phase 2 ADX-2191 trial results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-ALDX-003504 · Corrections policy